Study of antibiotics for resistant infections
Part of Infections clinical trials.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been treated for at least 48 hours with the antibiotics ceftazidime-avibactam (CAZ/AVI) or ceftazidime-avibactam plus fosfomycin (FOS).
- You have a confirmed infection with CRE bacteria.
- You sign a consent form to join the study.
- You do not have a mixed infection with other bacteria, unless all the bacteria are of the Enterobacterales type and are sensitive to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study tests whether giving antibiotics chosen specifically for your resistant bacteria before a liver transplant can prevent infections better than the usual standard antibiotics. It aims to improve recovery and lower the risk of serious infection after surgery.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
Hear when a new Gram Negative Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.